Production (Stage)
Context Therapeutics Inc.
CNTX
$0.6101
-$0.0193-3.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 15.30% | -4.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 28.27% | -76.95% | |||
| Operating Income | -28.27% | 76.95% | |||
| Income Before Tax | -36.93% | 80.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -36.93% | 80.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -36.93% | 80.85% | |||
| EBIT | -28.27% | 76.95% | |||
| EBITDA | -28.27% | 76.96% | |||
| EPS Basic | -17.89% | 81.19% | |||
| Normalized Basic EPS | -18.04% | 81.19% | |||
| EPS Diluted | 42.33% | 61.55% | |||
| Normalized Diluted EPS | -18.04% | 81.19% | |||
| Average Basic Shares Outstanding | 16.18% | 1.80% | |||
| Average Diluted Shares Outstanding | 16.18% | 1.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||